Physician profile
Ashish Mathur
NPI 1245329663
$6,189.85
in general payments reported to CMS, 2019-2025
35 companies · $90.52 in 2025
The $90.52 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $1,080 · 2021: $1,783 · 2022: $1,528 · 2023: $1,234 · 2025: $90.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.05 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $818.45 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $775.20 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $550.09 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $512.60 | 2019-2023 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $458.98 | 2021-2023 | |
| Glaxosmithkline, LLC. | $402.61 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $233.38 | 2021-2023 | Freestyle Libre |
| Alnylam Pharmaceuticals INC. | $185.98 | 2021-2023 | |
| Pfizer INC. | $171.89 | 2020-2023 | |
| Horizon Therapeutics Plc | $162.29 | 2019-2022 | |
| Lilly USA, LLC | $159.53 | 2021-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.64 | 2019-2023 | Jardiance |
| Allergan, INC. | $143.34 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $142.21 | 2022-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $128.27 | 2021-2023 | Xarelto, Spravato |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $124.96 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $121.98 | 2019-2020 | |
| Redhill Biopharma INC. | $113.24 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $100.76 | 2020-2021 | |
| Inari Medical, INC. | $91.46 | 2022 | |
| Avanir Pharmaceuticals, INC. | $82.27 | 2019 | |
| Dexcom, INC. | $81.93 | 2021-2023 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $72.55 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $70.40 | 2019-2023 | Seglentis, Livalo |
| Currax Pharmaceuticals LLC | $52.51 | 2020-2023 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.16 | 2019-2023 | Trulance, Xifaxan |
| Amarin Pharma, INC. | $43.13 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.20 | 2020-2021 | |
| Genentech USA, INC. | $30.84 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $29.55 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $28.12 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $17.78 | 2023 | Voquezna |
| Lundbeck LLC | $15.63 | 2022 | |
| Hologic Sales and Service, LLC | $15.60 | 2021 | |
| Eisai INC. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.